Method of eosinophil depletion with antibody to CCR 3 receptor
AssigneeSchering Corporation
InventorsJ. Christopher Grimaldi, Maureen C. Howard, Robert L. Coffman
Life of this patent
Estimating the term…
Abstract
Binding compositions and various methods of use of the binding compositions are provided. In particular, a method is provided which comprises administering an effective amount of the binding composition, alone or in combination with other compounds, to eosinophils, thereby reducing the level of eosinophils in an individual. Preferably, the binding composition is a monoclonal antibody specific for CCR3.
Claims10
A method of ameliorating an eosinophilia related disease or disorder in an individual comprising administering an effective amount of an antibody which specifically binds a CCR3 receptor;
- wherein said antibody is of the IgG2B isotype that reduces the level of eosinophils in said individual and does not block ligand binding to said receptor.
Dependencies are inferred from the claim text.